Apr. 15, 2016 OBIO® Executive Exchange Series: Creating Your Winning Go-to-Market Strategy – Learn from the Locemia Experience with Claude Piché and Martin Lafontaine
OBIO invites you to join us for this outstanding opportunity to learn from Claude Piché, CEO and Martin Lafontaine, CCO of Locemia Solutions. Locemia developed intranasal glucagon, a needle-free rescue treatment for severe hypoglycemia, to completion of Phase III clinical trial testing before it was acquired by Eli Lilly in late 2015.
In person over breakfast and by webinar, Claude and Martin will share their extensive experience on the importance of spending the time and resources to develop your go-to-market strategy as it is essential in setting up your business for success from a clinical and regulatory, financing and acquisition target perspective.
You will learn how developing your go-to-market strategy will enable you to:
• Build the commercial case for your product through conducting primary market research with patients, healthcare providers, payers and other stakeholders,
• Develop your operational plan including capital requirements, and
• Make your company attractive to investors and acquirers.
Join us and ask your questions!
Claude Piché is a seasoned executive with a broad base of hands-on experience in pharmaceutical operations, drug development, regulatory affairs, business development, marketing and fund raising. Prior to co-founding Locemia Solutions in 2012, Claude held positions including Executive VP, R&D with AMG Medical, Co-Founder of Promesa Bio, VP Clin/Reg with PR Pharmaceuticals and senior roles with Heska Corporation and Merck.
Martin Lafontaine is a life science commercial leader with more than 17 years of experience in the pharmaceutical and medical device industry, at the Canadian, US and International level, in both big pharma and start-ups, where he more recently held the role of CCO at Locemia Solutions, assuming a leadership role in developing the company's commercial strategy, planning and related valuation, supporting the business development efforts.